Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

被引:135
|
作者
Nolan, D
Upton, R
McKinnon, E
John, M
James, I
Adler, B
Roff, C
Vasikaran, S
Mallal, S [1 ]
机构
[1] Royal Perth Hosp, Dept Clin Immunol, Ctr Clin Immunol & Biomed Stat, Perth, WA 6000, Australia
[2] Murdoch Univ, Murdoch, WA 6150, Australia
[3] Royal Perth Hosp, Dept Nucl Med, Perth, WA, Australia
[4] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA, Australia
关键词
bone mineral density; HAART; indinavir; lipodystrophy syndrome; nelfinavir; protease inhibitors; osteopenia; osteoporosis; subcutaneous fat wasting;
D O I
10.1097/00002030-200107060-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients. Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04). Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between P1 therapy and decreased lumbar spine z-score. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1275 / 1280
页数:6
相关论文
共 50 条
  • [41] Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men
    L. C. Pezzaioli
    T. Porcelli
    A. Delbarba
    F. Maffezzoni
    E. Focà
    F. Castelli
    C. Cappelli
    A. Ferlin
    M. E. Quiros-Roldan
    Journal of Endocrinological Investigation, 2022, 45 : 433 - 443
  • [42] Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men
    Pezzaioli, L. C.
    Porcelli, T.
    Delbarba, A.
    Maffezzoni, F.
    Foca, E.
    Castelli, F.
    Cappelli, C.
    Ferlin, A.
    Quiros-Roldan, M. E.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (02) : 433 - 443
  • [43] Bone Mineral Density Increases in HIV-Infected Children Treated With Long-term Combination Antiretroviral Therapy
    Bunders, Madeleine J.
    Frinking, Olivier
    Scherpbier, Henriette J.
    van Arnhem, Lotus A.
    van Eck-Smit, Berthe L.
    Kuijpers, Taco W.
    Zwinderman, Aeilko H.
    Reiss, Peter
    Pajkrt, Dasja
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (04) : 583 - 586
  • [44] The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir
    Nouts, C
    Bonarek, M
    Morlat, P
    Delevaux, I
    Bonnet, F
    Lacoste, D
    Bernard, N
    Beylot, J
    INTERNATIONAL JOURNAL OF STD & AIDS, 2001, 12 (01) : 29 - 33
  • [45] AN OVERVIEW OF BONE DISEASE IN HIV-INFECTED PATIENTS
    Chitu-Tisu, Cristina-Emilia
    Barbu, Ecaterina-Constanta
    Lazar, Mihai
    Ionescu, Razvan
    Bojinca, Mihai
    Ion, Daniela Adriana
    Badarau, Ioana Anca
    ACTA MEDICA MEDITERRANEA, 2015, 31 (06): : 1139 - 1151
  • [46] Effects of Vitamin D Supplementation on Bone Mineral Density and Bone Markers in HIV-Infected Youth
    Eckard, Allison Ross
    O'Riordan, Mary Ann
    Rosebush, Julia C.
    Ruff, Joshua H.
    Chahroudi, Ann
    Labbato, Danielle
    Daniels, Julie E.
    Uribe-Leitz, Monika
    Tangpricha, Vin
    McComsey, Grace A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 76 (05) : 539 - 546
  • [47] Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals
    Gagnon, RF
    Alli, AI
    Edwardes, MD
    Watters, AK
    Tsoukas, CM
    CLINICAL NEPHROLOGY, 2006, 65 (01) : 13 - 21
  • [48] HIV and bone mineral density
    Mallon, Patrick W. G.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2010, 23 (01) : 1 - 8
  • [49] High frequency of hypovitaminosis D and low bone mineral density in a sample of HIV-infected men in Chile
    Perez, Carlos
    Ceballos, Maria Elena
    REVISTA CHILENA DE INFECTOLOGIA, 2014, 31 (01): : 44 - 46
  • [50] Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density
    Negredo, Eugenia
    Puig, Jordi
    Bonjoch, Anna
    Perez-Alvarez, Nuria
    Echeverria, Patricia
    Estany, Carla
    Cruz Pastor, Maria
    Luisa Granada, Maria
    Clotet, Bonaventura
    FUTURE VIROLOGY, 2012, 7 (11) : 1127 - 1134